FGP
KRYS icon

Freestone Grove Partners’s Krystal Biotech KRYS Stock Holding History

Freestone Grove Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$755K Buy
+2,922
New +$778K 0.01% 529
2025
Q4 		– Sell
-2,031
Closed -$359K – 834
2025
Q3 		$359K Buy
2,031
+136
+7% +$20.4K ﹤0.01% 587
2025
Q2 		$260K Buy
+1,895
New +$278K ﹤0.01% 604

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Grove Partners's KRYS Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Krystal Biotech (KRYS) in Q1 2026: 2,922 shares worth $755K. The stake represents 0.01% of the portfolio and ranks #529 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in KRYS as recently as Q3 2025.

Freestone Grove Partners first reported a position in KRYS in Q2 2025 and has held it in 3 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Freestone Grove Partners held 2,922 shares of Krystal Biotech worth $755K as of Q1 2026.
  • Krystal Biotech was a new Freestone Grove Partners position in Q1 2026.
  • Krystal Biotech made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #529 holding.
  • Freestone Grove Partners first reported a position in Krystal Biotech in Q2 2025 and has held it in 3 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.